STRATEGIC NEWS WATCH — August 31, 2026
|
Eli Lilly agreed to pay up to $2.875 billion for Merida Biosciences and its Phase 1 autoantibody-degrading platform, its fourth acquisition of 2026 and a wager on selectively clearing pathogenic autoantibodies rather than broadly suppressing immunity. Separately, the company reported Week 52 data extending its Taltz-plus-Zepbound combination over Taltz alone in psoriatic disease with obesity — though on exploratory, non-multiplicity-controlled analyses that cannot yet support a statistical claim. Today’s top developments:
|
What to Watch
- The VESALIUS-CV mortality hazard ratio — Amgen has released a 20% relative reduction without a hazard ratio or confidence interval, on an endpoint that was only hypothesis-generating in the primary NEJM publication; the full Circulation paper should supply the missing statistics, and the open question is whether payers accept a prespecified secondary mortality analysis as grounds to loosen PCSK9 restrictions.
- Redemplo’s glycemic signal — Worsening glucose control in 14.3% of patients is the entire analyst disagreement over Arrowhead’s plozasiran; look for a diabetes-subgroup breakout in the planned late-2026 supplemental FDA filing, and note how the agency weighs the finding against Ionis’s Tryngolza in a population with heavy diabetes overlap.
- Mimrylo versus phlebotomy economics — At roughly $218,000 a year against a procedure that is effectively free, payer coverage criteria are the variable to track — particularly whether they require prior hydroxyurea or interferon failure, which would cap the drug’s near-$2 billion peak estimate well short.
- Taltz-plus-Zepbound’s statistical gap — The Week 52 combination data are prespecified but exploratory and descriptive, without multiplicity control; the like-for-like PASI 100 (40.5% versus 29.1%) and ACR50 (43.7% versus 15.7%) separations are the numbers a confirmatory, formally-tested readout will need to reproduce before the combination can carry a claim in the large psoriatic-plus-obesity population.
- Personalized cancer vaccines by tumor type — BioNTech’s colorectal halt lands against Merck and Moderna’s melanoma win on the same neoantigen concept; the continuing pancreatic IMCODE003 readout will indicate how much read-through survives the colorectal failure, and full disclosure of the colorectal survival imbalance would help settle whether tumor immunogenicity, not the platform, is doing the work.
This brief highlights the edition’s top stories. Read the full August 31, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.